Clinical Research
Filter News
Found 148,046 articles
-
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
4/23/2024
Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia.
-
Kraig Biocraft Laboratories Successfully Completes Recombinant Cocoon Production From Spring Trials
4/22/2024
Kraig Biocraft Laboratories, Inc., announces what it considers to be a major milestone. The Company has completed rearing of the first generation of its new BAM-1 parental strains as part of its spring production trial.
-
Molecular You Announces Breakthrough in Early Detection of Pancreatic Cancer
4/22/2024
Molecular You has achieved a significant milestone in the early detection of pancreatic cancer.
-
First Ascent Biomedical’s New Study Shows Functional Precision Medicine Platform Identifies Effective Treatments for 83 Percent of Children with Difficult-to-Treat Cancers
4/22/2024
First Ascent Biomedical announced today results from a prospective clinical study conducted in partnership with Florida International University (FIU) using a unique and groundbreaking functional precision medicine (FPM) platform.
-
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
4/22/2024
NeuroSense Therapeutics Ltd. announced today a collaboration in Alzheimer's Disease (AD) drug development with Genetika+ , a leader in precision medicine for psychiatry and neurology.
-
Enrollment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial
4/22/2024
Actinogen Medical Limited (ASX: ACW) announces the full enrollment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD).
-
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
4/22/2024
ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced positive interim results from the Phase 2 study of eblasakimab in moderate-to-severe atopic dermatitis (AD) adult patients previously treated with dupilumab, TREK-DX.
-
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
4/22/2024
Krystal Biotech, Inc. announced today that the first patient was dosed in its Phase 1 clinical trial (KYANITE-1) evaluating inhaled KB707.
-
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
4/22/2024
Plus Therapeutics, Inc. today announced it has been selected for funding by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP).
-
Profluent Successfully Edits Human Genome with OpenCRISPR-1, the World’s First AI-Created and Open-Source Gene Editor
4/22/2024
Profluent, the AI-first protein design company, debuted the OpenCRISPRTM initiative, releasing the world’s first open-source, AI-generated gene editor.
-
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
4/22/2024
Centessa Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) to initiate a Phase 1 first-in-human, clinical trial of ORX750 for the treatment of narcolepsy.
-
XORTX Announces Publication of Key Research in ADPKD
4/22/2024
XORTX Therapeutics Inc. is pleased to announce a research paper titled “Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models" has been accepted for publication in the peer-reviewed American Journal.
-
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
4/22/2024
Tiziana Life Sciences, Ltd. today announced additional positive clinical results from its intermediate sized Expanded Access Program (EAP) for non-active secondary progressive multiple sclerosis (na-SPMS) patients.
-
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025Trial's lower-than-expected event rate suggests improved survival outcomes
4/22/2024
Panbela Therapeutics, Inc. today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025.
-
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
4/22/2024
Ipsen and Skyhawk Therapeutics announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases.
-
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
4/22/2024
Natera, Inc. today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera’s technology in the scientific literature.
-
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
4/22/2024
Lantern Pharma Inc. announced today that – the company has received regulatory approval to expand its Harmonic™ trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer.
-
Hyundai Bioscience announces its successful result from a preclinical study of a Niclosamide-based oral anticancer drug to treat triple-negative breast cancer
4/22/2024
Hyundai Bioscience announced the positive results from its preclinical study on triple-negative breast cancer, investigating combination therapy of 'Niclosamide-based oral anti-cancer drug' jointly developed with CNPharm and Docetaxel, one of widely-used chemical anticancer agents.
-
Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update
4/22/2024
Salubris Biotherapeutics, Inc. today announced a new capital infusion of $35 million to fund continued research and development of clinical and pre-clinical programs.
-
Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement
4/22/2024
Kynos Therapeutics Ltd announces the key findings from the first-in-human Phase I trial of its lead drug candidate, KNS366.